Insider · CIK 0001441461

Glickman Mark A

Reports to the SEC for 7 companies · POMPANO BEACH, FL

sec.gov

Transactions

Companies

Filings

CIK

0001441461

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-27	BSEMBioStem Technologies, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−7,671 sh	—	—	0
2026-08-27	BSEMBioStem Technologies, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+7,671 sh	—	—	7,671
2026-06-08	MTVAMetaVia Inc.A Award	Director	AAward	+17.2K sh	—	—	20,629
2025-06-30	MTVAMetaVia Inc.A Award	Director	AAward	+28.1K sh	—	—	37,887
2024-06-07	MTVAMetaVia Inc.A Award	Director	AAward	+5,051 sh	—	—	9,740
2023-07-27	MTVAMetaVia Inc.A Award	Director	AAward	+25K sh	—	—	25,000
2023-07-27	MTVAMetaVia Inc.A Award	Director	AAward	+12.5K sh	—	—	37,500
2022-12-06	TXMDTherapeuticsMD, Inc.S Sale	Co-Chief Executive Officer	SSale	−440 sh	$4.92	−$2,165.46	1,294
2022-12-06	TXMDTherapeuticsMD, Inc. · Restricted Stock UnitsM Exercise/Conversion	Co-Chief Executive Officer	MExercise/Conversion	−1,734 sh	—	—	3,466
2022-12-06	TXMDTherapeuticsMD, Inc.M Exercise/Conversion	Co-Chief Executive Officer	MExercise/Conversion	+1,734 sh	—	—	1,734
2022-03-31	TXMDTherapeuticsMD, Inc. · Performance Stock UnitsA Award	Co-Chief Executive Officer	AAward	+260K sh	—	—	260,000
2022-03-23	TXMDTherapeuticsMD, Inc. · Restricted Stock UnitsA Award	Co-Chief Executive Officer	AAward	+260K sh	—	—	260,000
2021-10-15	TXMDTherapeuticsMD, Inc. · Restricted Stock UnitsA Award	Co-Chief Executive Officer	AAward	+400K sh	—	—	400,000
2021-10-15	TXMDTherapeuticsMD, Inc. · Performance Stock UnitsA Award	Co-Chief Executive Officer	AAward	+260K sh	—	—	260,000
2021-10-15	TXMDTherapeuticsMD, Inc. · Restricted Stock UnitsA Award	Co-Chief Executive Officer	AAward	+260K sh	—	—	260,000
2020-01-02	ESPREsperion Therapeutics, Inc. · Stock Option (right to buyA Award	Chief Commercial Officer	AAward	+26.6K sh	—	—	26,625
2020-01-02	ESPREsperion Therapeutics, Inc.A Award	Chief Commercial Officer	AAward	+5,925 sh	—	—	25,925
2018-03-19	Old API Wind-down Ltd.S Sale	Chief Commercial Officer	SSale	−5,725 sh	$1.70	−$9,732.5	250,188
2017-05-11	Old API Wind-down Ltd.Employee Stock Option (right to buy)A Award	Chief Commercial Officer	AAward	+92.6K sh	—	—	92,621
2017-05-11	Old API Wind-down Ltd.A Award	Chief Commercial Officer	AAward	+80.2K sh	—	—	255,913
2016-06-22	Old API Wind-down Ltd.F Tax Payment	Chief Commercial Officer	FTax Payment	−10.8K sh	$3.34	−$36.1K	175,750
2016-05-16	Old API Wind-down Ltd.P Purchase	Chief Commercial Officer	PPurchase	+25K sh	$3.68	+$92.1K	186,553
2016-03-17	Old API Wind-down Ltd.Stock Options (right to buy)A Award	Chief Commercial Officer	AAward	+38.6K sh	—	—	38,559
2016-03-17	Old API Wind-down Ltd.A Award	Chief Commercial Officer	AAward	+45.6K sh	—	—	161,553
2016-02-12	Old API Wind-down Ltd.A Award	Chief Commercial Officer	AAward	+86.9K sh	—	—	116,000
2016-02-05	Old API Wind-down Ltd.J Other	Chief Commercial Officer	JOther	+29.1K sh	—	—	29,137
2015-06-22	POZEN INC /NCA Award	Chief Commercial Officer	AAward	+29.1K sh	—	—	29,137
2015-01-29	AUXILIUM PHARMACEUTICALS INCNonqualified Employee Stock Option (Right To Buy)J Other	EVP - Sales and Marketing	JOther	−31.2K sh	$36.53	−$1.14M	0
2015-01-29	AUXILIUM PHARMACEUTICALS INCNonqualified Employee Stock Option (Right to Buy)J Other	EVP - Sales and Marketing	JOther	−24.8K sh	$36.53	−$904K	0
2015-01-29	AUXILIUM PHARMACEUTICALS INCNonqualified Employee Stock Option (Right to Buy)J Other	EVP - Sales and Marketing	JOther	−5,000 sh	$36.53	−$183K	0
2015-01-29	AUXILIUM PHARMACEUTICALS INCNonqualified Employee Stock Option (Right to Buy)J Other	EVP - Sales and Marketing	JOther	−27.5K sh	$36.53	−$1M	0
2015-01-29	AUXILIUM PHARMACEUTICALS INCJ Other	EVP - Sales and Marketing	JOther	−27.9K sh	$36.53	−$1.02M	0
2014-11-20	AUXILIUM PHARMACEUTICALS INCM Exercise/Conversion	EVP - Sales and Marketing	MExercise/Conversion	+8,250 sh	$18.30	+$151K	75,863
2014-11-20	AUXILIUM PHARMACEUTICALS INCM Exercise/Conversion	EVP - Sales and Marketing	MExercise/Conversion	+5,000 sh	$26.87	+$134K	67,613
2014-11-20	AUXILIUM PHARMACEUTICALS INCM Exercise/Conversion	EVP - Sales and Marketing	MExercise/Conversion	+27.5K sh	$20.07	+$552K	62,613
2014-11-20	AUXILIUM PHARMACEUTICALS INCS Sale	EVP - Sales and Marketing	SSale	−7,202 sh	$33.18	−$239K	68,661
2014-11-20	AUXILIUM PHARMACEUTICALS INCS Sale	EVP - Sales and Marketing	SSale	−40.8K sh	$33.16	−$1.35M	27,911
2014-11-20	AUXILIUM PHARMACEUTICALS INCNonqualified Stock Option (Right to Buy)M Exercise/Conversion	EVP - Sales and Marketing	MExercise/Conversion	−27.5K sh	—	—	27,500
2014-11-20	AUXILIUM PHARMACEUTICALS INCNonqualified Stock Option (Right to Buy)M Exercise/Conversion	EVP - Sales and Marketing	MExercise/Conversion	−5,000 sh	—	—	5,000
2014-11-20	AUXILIUM PHARMACEUTICALS INCNonqualified Stock Option (Right to Buy)M Exercise/Conversion	EVP - Sales and Marketing	MExercise/Conversion	−8,250 sh	—	—	24,750
2014-02-18	AUXILIUM PHARMACEUTICALS INCA Award	EVP - Sales and Marketing	AAward	+12.5K sh	—	—	35,113
2014-02-18	AUXILIUM PHARMACEUTICALS INCA Award	EVP - Sales and Marketing	AAward	+12.5K sh	—	—	35,113
2014-02-18	AUXILIUM PHARMACEUTICALS INCRestricted Stock Units (Performance Based)A Award	EVP - Sales and Marketing	AAward	+24K sh	—	—	24,000
2014-02-18	AUXILIUM PHARMACEUTICALS INCNonqualified Stock Option (Right to Buy)A Award	EVP - Sales and Marketing	AAward	+31.2K sh	—	—	31,200
2014-02-18	AUXILIUM PHARMACEUTICALS INCF Tax Payment	EVP - Sales and Marketing	FTax Payment	−704 sh	$28.30	−$19.9K	22,613
2014-02-18	AUXILIUM PHARMACEUTICALS INCA Award	EVP - Sales and Marketing	AAward	+6,375 sh	—	—	23,317
2014-02-07	AUXILIUM PHARMACEUTICALS INCF Tax Payment	EVP - Sales and Marketing	FTax Payment	−1,986 sh	$23.68	−$47K	16,942
2014-02-03	AUXILIUM PHARMACEUTICALS INCF Tax Payment	EVP - Sales and Marketing	FTax Payment	−388 sh	$24.70	−$9,583.6	18,928
2013-02-07	AUXILIUM PHARMACEUTICALS INCA Award	EVP - Sales and Marketing	AAward	+13.2K sh	—	—	19,742
2013-02-07	AUXILIUM PHARMACEUTICALS INCA Award	EVP - Sales and Marketing	AAward	+13.2K sh	—	—	19,742

Recent filings

Accepted (ET)
Aug 284
Glickman Mark A0001441461-26-000005
SEC(opens sec.gov)
Jun 84
Glickman Mark A0001104659-26-071469
SEC(opens sec.gov)
Jul 14
Glickman Mark A0001104659-25-064716
SEC(opens sec.gov)
Jun 74
Glickman Mark A0001104659-24-069785
SEC(opens sec.gov)
Jul 284
Glickman Mark A0001104659-23-084974
SEC(opens sec.gov)
Dec 94
Glickman Mark A0001209191-22-060586
SEC(opens sec.gov)
Mar 314
Glickman Mark A0001209191-22-021793
SEC(opens sec.gov)
Mar 284
Glickman Mark A0001209191-22-021212
SEC(opens sec.gov)
Oct 154
Glickman Mark A0001209191-21-060610
SEC(opens sec.gov)
Jan 34
Glickman Mark A0001179110-20-000171
SEC(opens sec.gov)
Mar 214
Glickman Mark A0001104659-18-019362
SEC(opens sec.gov)
May 124
Aralez Pharmaceuticals Inc.0001104659-17-032415
SEC(opens sec.gov)

Companies

Address

C/O BIOSTEM TECHNOLOGIES, INC. 2836 CENTER PORT CIRCLE

POMPANO BEACH, FL, 33064